Whole-body magnetic resonance imaging (MRI) may serve as a valuable noninvasive tool for assessing the risk of heart attack and stroke in diabetic patients, according to a new clinical study published online in the journal Radiology. 

The Potential of PET/MR

The addition of magnetic resonance (MR) imaging and spectroscopy to positron emission tomography (PET) is more expensive and more technically challenging compared with PET/computed tomography (CT). PET/CT is successful because the inclusion of CT has major advantages: accurate lesion localization, the identification of non-PET avid lesions and effective attenuation correction in a rapid, efficient combined examination. The addition of CT is particularly valuable for lungs and liver, where fluorodeoxyglucose (FDG) PET is limited by spatial resolution and relatively low target-to-background differential biodistribution. Presumably, PET/MR may disclose unique important diagnostic and prognostic information in selected patient groups.
Stock image
STOCK IMAGE

During the American College of Cardiology 2013 (ACC.13) annual meeting in March, vendors discussed several trends they are observing in the cardiac ultrasound market and displayed the latest echo advances.

Imaging the World (ITW) was founded in 2008. Its mission is to bring medical expertise and high-quality, low-cost health care to most remote and under-served areas worldwide by integrating simple ultrasound technology with training, local capacity building and community support. It is much more than modern technology alone — it is a system solution. 

With concerns about radiation dose and reducing unnecessary imaging scans, advances in computed tomography (CT) systems have brought about technologies such as iterative reconstruction software, intraoperative capabilities and dose-tracking software. In addition, recent studies on the use of CT on select patient populations and the modality’s benefits in detecting certain cancers are showing that the risks of CT imaging can go both ways. While CT exams can add to a patient’s lifetime exposure to ionizing radiation, they can also be more beneficial in cases where magnetic resonance imaging (MRI) or ultrasound might not be able to detect early-stage cancers. Some of these trends in utilization indicate that appropriate low-dose CT imaging will be key across patient populations.

Based on its recent analysis of the molecular imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2013 North American Frost & Sullivan Award for Company of the Year. Siemens Healthcare has dedicated equal attention and resources to the development of both single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging – the two pillars of molecular imaging. The company has moved quickly to innovate and strategize in a rapidly evolving market to secure for itself an ideal market position.


ITN is proud to go pink this month in an effort to help bring attention to Breast Cancer Awareness Month. This disease all too often hits home with the imaging and radiation oncology markets.

This year at RSNA 2013, GE Healthcare will showcase its SenoBright Contrast Enhanced Spectral Mammography (CESM) technology designed to produce contrast-enhanced images of the breast using an approved X-ray contrast agent and a dual energy acquisition technique. This technology is experiencing increased adoption globally and in the United States, and GE Healthcare will present, in its booth, an informational campaign designed for American women with a history of breast cancer and their relatives, and those who want to know about the latest options in diagnostics.

Radiation therapy clinical trial study whole brain radiotherapy

Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now